{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"23"}]}],"title":"PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"description":"OR is defined as the number of participants achieving either a CR (the disappearance of all target lesions) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters \\[e.g., percent change from Baseline\\]) per modified RECIST, version 1.1. To determine the OR, the extracranial response was combined with the intracranial response. Confirmation assessments were to be performed no less than 4 weeks after the criteria for response were initially met and may have been performed at the next protocol-scheduled assessment. Participants who had an overall response of not evaluable or a missing response were treated as non-responders.","groups":[{"description":"Participants who received no prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.","id":"OG000","title":"GSK2118436 150 mg: No Prior Local Therapy"},{"description":"Participants who received prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.","id":"OG001","title":"GSK2118436 150 mg: Prior Local Therapy"}],"paramType":"NUMBER","populationDescription":"V600E Population","reportingStatus":"POSTED","timeFrame":"From the time of the Baseline assessment until disease progression or end of study treatment (average of 24 weeks)","title":"Number of Participants With V600E Mutation-positive Melanoma With a Best Overall Response (OR) of CR or PR, as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"participants"}